Interestingly, both LILRB4/CD85k and CD33 are therapeutic targets in AML [57–63] and have shown potential as therapeutic vulnerabilities in KMT2A-rearranged ALL. This evidence concerns the gene LILRB4 and acute myeloid leukemia.